CHMP Says No to Teva and Active Biotech's Nerventra | 2014-01-28 | FDANews | FDAnews
Laquinimod - Wikipedia
Teva Pharmaceutical Industries Ltd. Active Biotech AB Web Site: www.tevapharm.com Web Site: www.activebiotech.com ______
Teva, Active Biotech enrol first patient in RRMS drug Phase III study - Clinical Trials Arena
Active Biotech regains rights of laquinimod from Teva
1 DISCIPLINARY COMMITTEE RULING February 10, 2012 AT NASDAQ OMX STOCKHOLM 2012:2 NASDAQ OMX Stockholm AB Active Biotech AB The s
Teva abandons development of laquinimod after multiple failures
ANNUAL REPORT 2020 | ACTIVE BIOTECH AB
Weekly Biotech Report covering Vantrela by Teva Pharmaceutical Industries Ltd. (ADR) (NYSE:TEVA) - Market Exclusive
Active Biotech and Ipsen to present
Prostate Cancer Therapeutics Market Competitive Landscape
Active Biotech and Teva remain committed to clinical development program for multiple sclerosis
Production at Teva API plant halted until next year | Fierce Pharma
Teva drops development of laquinimod - PharmaTimes
CHMP says no to Laquinimod
Teva takes $215M hit from currency effects
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Teva, Active Biotech Partner To Develop Laquinimod For Huntington's Disease
Active Biotech's partner Teva starts laquinimod clinical trial
Fortified with sentiment and cash, Active Biotech presses on | Evaluate
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
Heart Incidents End Parts of Two Studies by Teva, Active Biotech - WSJ
Teva returns laquinimod global rights to Active Biotech
